3 October 2024
Cizzle Biotechnology Holdings
plc
("Cizzle", "Cizzle
Biotechnology", or the "Company")
Further Update on Strategic Licensing
and Partnership Agreement for North America
Cizzle Biotechnology, the UK based diagnostics
developer, today provides a further update on progress with the
Company's planned strategic and exclusive licensing partner in the
USA, Cizzle Bio Inc ("BIO").
Following the Company's signing of a memorandum
of understanding ("MoU")
with BIO announced on 2 April 2024 and the 60 day extension to
finalise a full and binding license agreement (the "Agreement") announced on 25 July 2024,
the Company has continued to support BIO's plans to market the
Company's CIZ1B biomarker and to complete the Agreement. The final
details of the Agreement are expected to be completed shortly, at
which time the Company will make a further announcement.
In the meantime, BIO continues to attract
significant clinical interest to build on the recent collaboration
with Moffitt Cancer Center, the number one cancer hospital in
Florida and the Southeast USA, to test patients with suspicious
lung nodules, as announced on 9 September 2024.
Enquiries:
|
Cizzle Biotechnology Holdings plc
|
Via IFC Advisory
|
|
Allan Syms (Executive
Chairman)
|
|
|
Allenby Capital Limited
|
+44(0) 20 3328 5656
|
|
John Depasquale/George Payne
(Corporate Finance)
|
|
|
Stefano Aquilino/Amrit Nahal (Sales
and Corporate Broking)
|
|
|
IFC
Advisory Limited
|
+44(0) 20 3934 6630
|
|
Tim Metcalfe
|
|
|
Florence Chandler
|
|
|
|
| |
About Cizzle
Biotechnology
Cizzle is developing a blood test to help in
the early detection of lung cancer. Based on the pioneering work of
Professor Coverley and colleagues, at the University of York,
on a naturally occurring cell nuclear protein involved in DNA
replication called CIZ1, they discovered that a variant called
CIZ1B is highly associated with the presence of early-stage cancer.
The company has now entered into commercial royalty bearing
licensing agreements and collaborations with leading centres of
excellence in cancer for the use of its proprietary technology as
part of its strategy to bring its non-intrusive, cost-effective
blood test to market. Cizzle was admitted to the Standard segment
of the main market of the London Stock Exchange in May
2021.
For more information, please see
https://cizzlebiotechnology.com
You can also follow the Company through its
twitter account @CizzlePlc and on LinkedIn.
About Cizzle Bio Inc
Cizzle Bio Inc, a company registered
in Texas USA, stands at the forefront of biotechnological
innovation, dedicated to revolutionizing the detection of lung
cancer through groundbreaking diagnostic tools. With exclusive
rights to detect the CIZ1B Biomarker in the USA and Canada, we are
driven by a commitment to improve early cancer detection and
enhance patient outcomes.